Striatal dopamine D2 receptor occupancy induced by daily application of blonanserin transdermal patches: Phase 2 study in Japanese patients with schizophrenia

The International Journal of Neuropsychopharmacology
Hironori NishibeYoshiro Okubo


Transdermal antipsychotic patch formulations offer potential benefits, including improved adherence. This study investigated the striatal dopamine D2 receptor occupancy with daily blonanserin transdermal patch application. This open-label, Phase 2 study enrolled 18 Japanese outpatients (20 to <65 years) with schizophrenia (DSM-IV-TR criteria; total Positive and Negative Syndrome Scale [PANSS] score <120 at screening) treated with blonanserin 8 mg or 16 mg tablets. Patients continued tablets for 2-4 weeks at their current dose and were then assigned to once-daily blonanserin patches (10/20/40/60/80 mg daily) for 2-4 weeks based on the oral dose. [ 11C]raclopride PET scanning determined blonanserin striatal dopamine D2 receptor occupancy (primary endpoint). Secondary endpoints included assessment of receptor occupancy by dose, changes in PANSS and CGI-S scores, patient attitudes towards adherence, and patch adhesiveness. Of 18 patients who started the blonanserin tablet treatment period, 14 patients completed treatment. Mean D2 receptor occupancy for blonanserin tablets 8 mg/day (59.2%, n=5) and 16 mg/day (66.3%, n=9) was within the values for blonanserin patches: 10 mg/day (33.3%, n=3), 20 mg/day (29.9%, n=2), 40 mg/day (61.2%, ...Continue Reading


Apr 3, 2001·The International Journal of Neuropsychopharmacology·Tetsuya SuharaLars Farde
Jan 12, 2002·Archives of General Psychiatry·Tetsuya SuharaLars Farde
Dec 25, 2009·CNS Drugs·Emma D Deeks, Gillian M Keating
Apr 5, 2012·Archives of General Psychiatry·Oliver D HowesShitij Kapur
Apr 1, 2011·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Mizuho SekineTetsuya Suhara
Jul 17, 2013·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Sakae TakahashiMakoto Uchiyama
Sep 24, 2013·Neurobiology of Disease·Richard J Hargreaves, Eugenii A Rabiner
Apr 4, 2015·Journal of Pharmacological Sciences·Satoko BabaMichiko Ono
Sep 20, 2017·Journal of Psychopharmacology·Yusuke NakataMasaomi Iyo
Jul 19, 2019·The Journal of Clinical Psychiatry·Leslie CitromeChristoph U Correll

Related Concepts

Clinical Study by Phase
Screening Generic
Antipsychotic Agents
Surgical Patch
Therapeutic procedure
Positive and negative syndrome scale

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.